论文部分内容阅读
目的观察奥沙利铂联合替吉奥治疗老年晚期胃癌的有效性及安全性。方法将2010年1月至2011年10月间收治的老年晚期胃癌患者84例,随机分为观察组和对照组,每组42例。观察组采用奥沙利铂联合替吉奥化疗,对照组采用奥沙利铂联合氟尿嘧啶(FOLFOX4)方案化疗,所有患者均化疗2周期后评价疗效及毒副作用。结果观察组和对照组有效率分别为61.9%和59.5%,两组疗效比较差异无显著性。两组均出现胃肠道反应及骨髓抑制,观察组的发生率及严重程度均低于对照组,差异有显著性(P<0.05)。结论奥沙利铂联合替吉奥治疗老年晚期胃癌近期疗效好,不良反应可耐受,且用药方便,住院时间短,值得临床推广应用。
Objective To observe the efficacy and safety of oxaliplatin combined with tiagre in the treatment of elderly patients with advanced gastric cancer. Methods From January 2010 to October 2011, 84 elderly patients with advanced gastric cancer were randomly divided into observation group and control group, with 42 cases in each group. The observation group was treated with oxaliplatin combined with tiagogli and the control group was treated with oxaliplatin plus fluorouracil (FOLFOX4) chemotherapy. All patients were evaluated for efficacy and side effects after 2 cycles of chemotherapy. Results The effective rates of the observation group and the control group were 61.9% and 59.5% respectively, with no significant difference between the two groups. Gastrointestinal reaction and myelosuppression were observed in both groups. The incidence and severity of the observation group were lower than those of the control group (P <0.05). Conclusion The combination of oxaliplatin and tioguanide in the treatment of elderly patients with advanced gastric cancer has good curative effect and adverse reactions. The combination of oxaliplatin and tegaserod has the advantages of convenient administration and short hospital stay, which is worthy of clinical application.